Envestnet Asset Management Inc. Trims Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Envestnet Asset Management Inc. reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) by 1.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,320 shares of the company’s stock after selling 236 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Intellia Therapeutics were worth $1,104,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of NTLA. Viking Global Investors LP boosted its position in Intellia Therapeutics by 56.3% during the 1st quarter. Viking Global Investors LP now owns 2,468,760 shares of the company’s stock valued at $179,405,000 after acquiring an additional 889,224 shares in the last quarter. State Street Corp lifted its position in Intellia Therapeutics by 30.2% during the 1st quarter. State Street Corp now owns 2,397,527 shares of the company’s stock worth $174,228,000 after acquiring an additional 556,076 shares during the period. ARK Investment Management LLC lifted its position in Intellia Therapeutics by 5.9% during the 2nd quarter. ARK Investment Management LLC now owns 9,514,580 shares of the company’s stock worth $439,003,000 after acquiring an additional 533,551 shares during the period. Citigroup Inc. lifted its position in Intellia Therapeutics by 415.8% during the 1st quarter. Citigroup Inc. now owns 338,786 shares of the company’s stock worth $24,620,000 after acquiring an additional 273,107 shares during the period. Finally, Polar Capital Holdings Plc acquired a new stake in Intellia Therapeutics during the 1st quarter worth about $18,713,000. 88.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Morgan Stanley reduced their price objective on Intellia Therapeutics from $84.00 to $83.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. JPMorgan Chase & Co. assumed coverage on Intellia Therapeutics in a research note on Wednesday, September 21st. They set an “overweight” rating and a $85.00 price objective for the company. Raymond James reduced their price objective on Intellia Therapeutics from $127.00 to $124.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. StockNews.com assumed coverage on Intellia Therapeutics in a research note on Wednesday, October 12th. They set a “sell” rating for the company. Finally, Chardan Capital lifted their price objective on Intellia Therapeutics from $121.00 to $129.00 and gave the company a “buy” rating in a research note on Monday, November 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.72.

Intellia Therapeutics Trading Up 2.0 %

NTLA stock opened at $49.89 on Thursday. Intellia Therapeutics, Inc. has a 12-month low of $37.08 and a 12-month high of $130.33. The stock has a market cap of $3.93 billion, a price-to-earnings ratio of -8.50 and a beta of 1.83. The business’s 50-day moving average is $54.27 and its 200 day moving average is $55.10.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.18). The company had revenue of $13.27 million for the quarter, compared to analyst estimates of $13.60 million. Intellia Therapeutics had a negative return on equity of 47.79% and a negative net margin of 859.92%. As a group, equities analysts forecast that Intellia Therapeutics, Inc. will post -6.08 EPS for the current fiscal year.

Intellia Therapeutics Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Read More

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.